Deutetrabenazine treatment was generally well tolerated, with most AEs considered mild or moderate in severity and low incidences of AEs commonly observed in patients with TD and VMAT2 inhibitor class–related AEs, including depression and parkinsonism. The gene discussed is SLC18A2; the disease is Parkinson disease.